XOMA Corp (XOMAP) Stock Analysis

XOMA Corp (XOMAP) is a publicly traded company in the HEALTHCARE sector. It trades at $25.39, a price-to-earnings ratio of 25.43. This page summarizes the public market data, fundamentals, and frequently asked questions for XOMAP, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $25.39
• P/E Ratio: 25.43
• EPS: $1.00
• 52-Week High: $28.22
• 52-Week Low: $23.46

Market Sentiment

XOMA Corp currently has a Neutral sentiment score of 0.01.

About XOMA Corp

XOMA Corporation (XOMAP) is a biotechnology firm headquartered in Emeryville, California, specializing in the discovery and development of breakthrough therapeutic candidates. As a prominent royalty aggregator, XOMA strategically partners with global entities to enhance its proprietary technologies and expand its robust pipeline of innovative treatments across various therapeutic areas. With a strong focus on creating value through collaborations and royalty agreements, the company is well-po...

GNG Research Analysis

GNG Research scores XOMA Corp (XOMAP) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for XOMAP.

Frequently Asked Questions

Does XOMAP pay dividends?

XOMA Corp (XOMAP) does not currently pay a regular dividend.

What is XOMAP's P/E ratio?

XOMA Corp has a price-to-earnings (P/E) ratio of 25.43.